AUTOLOGOUS BONE MARROW TRANSPLANTS--BREAST/OVARY CANCER

本计划项目资助申请申请继续资助 PPG CA-47741用于自体骨大剂量化疗的研究 骨髓支持在乳腺癌和卵巢癌治疗中的应用该计划 由四个项目和三个核心活动组成，这些项目和活动具有高度的 相互关联、相互依存、相互作用。在项目IA中，我们建议(1) 完成第四阶段和第二阶段的前瞻性随机对照试验 根据第一次申请和(2)资助开始的Il期乳腺癌 扩大大剂量化疗和自体骨髓的使用 通过三种方式提供支持：(A)对患有癌症的患者进行大剂量治疗 原发乳癌累及4至9个腋窝淋巴结及(B)至 骨科疾病患者的随机对照试验；(C) 探索第二个大剂量化疗方案的使用。 在Lb计划中，我们评估了大剂量化疗对卵巢的作用 临床试验中的癌症从晚期疾病进展到患者 疾病仍然停留在第二次手术和基础研究中 旨在提高烷基化剂的功效。在……里面 项目二，我们调查了恶性污染的检测 用免疫学方法检测骨髓和外周血中的肿瘤细胞 方法并利用药理学和免疫学方法去除这些 骨髓中的恶性细胞。在项目IIIA中，我们建议研究 细胞因子和时间表的新组合扩大了我们的观察范围 乳腺癌患者外周血造血祖细胞经脑脊液刺激后的变化 正在接受高剂量化疗并将使用体外扩增的癌症 干细胞富集祖细胞与Emly作用的细胞因子提供 大剂量治疗后用于支持的细胞和详细研究 细胞因子及其受体的分布。该计划项目是 得到冷冻保存、统计和管理核心的支持。

This program project grant application applies for continued funding for PPG CA-47741 for studies of high dose chemotherapy in autologous bone marrow support in the treatment of breast and ovarian cancer. The program consists of four projects and three core activities which are highly interrelated, dependent and interactive. In Project IA we propose to (1) complete the prospective randomized, comparative trials in Stage IV and Stage Il breast cancer begun as funded under the first application and (2) extend the use of high dose chemotherapy and autologous bone marrow support in three ways: (a) to apply high dose therapy to patients with primary breast cancer involving four to nine axillary nodes and (b) to patients with bone only disease in a randomized comparative trial; (c) to explore the use of a second high-dose chemotherapy regimen used in tandem. In Project lB, we evaluate the role of high-dose chemotherapy for ovarian cancer in clinical trials progressing from advanced disease to patients with disease remaining at second look surgery and through basic research targeted at the enhancement of the efficacy of alkylating agents. In Project II, we investigate the detection of malignant contamination of the bone marrow and peripheral blood with neoplastic cells using immunologic methods and utilize pharmacologic and immunologic methods to remove these malignant cells from the marrow. In Project IIIA, we propose studies of new combination of cytokines and schedule to extend our observations of CSF primed peripheral blood progenitor cells in patients with breast cancer undergoing high dose chemotherapy and will use ex vivo expansion of stem-cell enriched progenitors with emly acting cytokines to provide cells for support after high-dose therapy and to study in detail the distribution of cytokines and their receptors. The program project is supported by cryopreservation, statistical and administrative cores.